



Novartis India Limited
Registered Office:
Sandoz House
Shivsagar Estate
Dr. Annie Besant Road
Worli, Mumbai 400 018
India
Tel +91 22 2495 8888
Fax +91 22 2495 0221
CIN No. L24200MH1947PLC006104
Website: www.novartis.in
Email: india.investors@novartis.com

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

July 28, 2016

Press Release

Dear Sirs,

We enclose a copy of press release on "Novartis India Limited announces Q1 2016-17 Results"; for your information.

Thanking you

Yours sincerely,

For Novartis India Limited

A handwritten signature in blue ink, appearing to read "Monaz Noble".

Monaz Noble
Whole Time Director &
Chief Financial Officer

A handwritten signature in black ink, appearing to read "Girish Tekchandani".

Girish Tekchandani
Company Secretary &
Compliance Officer

Encl.: a/a



Novartis India Limited
Registered Office
Sandoz House
Shivsagar Estate
Dr Annie Besant Road
Worli, Mumbai 400 018
India

MEDIA RELEASE • MEDIA RELEASE • MEDIA RELEASE

Novartis India announces Q1 2016-17 Results

At a meeting held in Mumbai today, the Board of Directors of Novartis India Limited (the "Board") approved results for the quarter ended 30 June 2016. Post divestment of the OTC and Animal Health businesses, Novartis India Limited (the "Company") operates in a single business segment which is Pharmaceuticals in India. Accordingly, no separate disclosures of segment information have been made. During the period under review, the Company recorded Total Income from Operations of ₹ 171.3 crore as against ₹ 222.9 crore in the previous corresponding quarter. Total Income from Operations was down by 23% as the previous corresponding quarter includes income from the divested businesses of OTC and Animal Health as well as the impact of price controls.

During the quarter under review the Company recorded a Profit from Operations of ₹ 8.5 crore as compared to Profit from Operations of ₹ 0.02 crore during the corresponding period of the previous year. Increase in Profit from Operations is mainly due to divestment of OTC and Animal Health businesses which had reported a loss of ₹ 5.5 crore during the corresponding period of the previous year. The Company registered Net Profit after Other Income of ₹ 19.1 crore as against ₹ 13.3 crore in the previous corresponding period.

Issued by Corporate Communications on 28 July 2016

Media contacts

Svetlana Pinto

+91-22-24951074 (direct)

+91-98210 54884 (mobile)

Email: svetlana.pinto@novartis.com

Liana Albuquerque

+91 22 24939403 (direct)

+91 98214 36458 (mobile)

liana.albuquerque@novartis.com